丙肝治疗未获持续病毒学应答与患者报告结局恶化相关
本研究纳入临床试验中接受直接抗病毒药物治疗未获持续病毒学应答(SVR)的丙肝患者242例,前瞻性随访健康相关生活质量(HRQL)。治疗结束时HRQL显著下降,入组时恢复至治疗前水平,但随访第24周和第48周再次显著下降,且肝硬化患者更明显。未获SVR者长期HRQL恶化,再治疗对改善临床结局和生活质量均重要。
要点
- 未获SVR的丙肝患者长期随访中HRQL持续恶化
- 肝硬化患者HRQL下降幅度更大
- 再治疗不仅改善临床结局也改善生活质量
核心结论
- 丙肝患者直接抗病毒药物治疗未获SVR后,长期随访中HRQL评分恶化,肝硬化者更明显。
研究设计与样本
- 长期注册研究(NCT01457768)纳入临床试验中完成治疗未获SVR的丙肝患者242例,中位年龄54岁(标准差±8岁),85%男性,38%肝硬化,前瞻性收集SF-36量表HRQL评分。
主要发现
- 治疗前HRQL评分与一般人群常模相似(所有单侧P>0.05),治疗结束时5/8 HRQL领域和心理总结评分显著下降(-3.4至-6.2分,P<.05)。
- 入组注册时除1项外所有HRQL平均评分恢复至治疗前水平(P>0.05)。
- 注册随访第24周所有HRQL领域下降达-9.2分(P<.05),第48周5/8领域下降达-8.3分(P<.05)。
- HRQL下降在肝硬化与非肝硬化患者中均可见,但肝硬化患者在3/8 HRQL领域更明显(P<.05)。
临床怎么用
- 对直接抗病毒药物治疗未获SVR的丙肝患者应关注长期生活质量恶化,再治疗可能同时改善临床结局与HRQL。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The causative relationship between the clearance of infections and long-term, health-related quality-of-life (HRQL) improvements in patients with hepatitis C virus (HCV) has been generally accepted. The aim of this study was to assess long-term HRQL trends in HCV patients who did not achieve sustained virologic responses (SVRs) after treatment with direct-acting antivirals. METHODS: HCV patients who completed treatment in clinical trials and did not achieve SVRs were enrolled in a long-term registry (#NCT01457768). HRQL scores were prospectively collected using the short form-36 instrument (8 HRQL domains and 2 summary scores). RESULTS: There were 242 patients included: they had a median age of 54 years (standard deviation ± 8 years), 85% were male, and 38% had cirrhosis. Before treatment, patients' HRQL scores were similar to the general population norms (all 1-sided P > 0.05), but were followed by significant decreases by the end of treatment (-3.4 to -6.2 points; P < .05 for 5/8 HRQL domains and mental summary). By the time subjects entered the registry, all but 1 of the mean HRQL scores had returned to their pretreatment levels (P > .05). During subsequent periods in the registry, patients experienced further HRQL decrements: up to -9.2 points (P < .05 for all HRQL domains) at Week 24 and up to -8.3 points (P < .05 for 5/8 HRQL domains) at Week 48. Although these HRQL decrements were observed regardless of cirrhosis status, they were more pronounced in patients with cirrhosis (P < .05 for 3/8 HRQL domains). CONCLUSIONS: Patients who did not achieve an SVR after treatment experienced worsening HRQL scores in long-term follow-ups. Retreatment of these patients will be important not only to improve their clinical outcomes, but also their quality of life.
引用
- Younossi ZM, Stepanova M, Jacobson I, et al. Not Achieving Sustained Viral Eradication of Hepatitis C Virus After Treatment Leads to Worsening Patient-reported Outcomes. Clin Infect Dis. 2020. PMID: 30949674. doi:10.1093/cid/ciz243
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。